fatnews.com Home page  >  Article | Previous article | Next article

SEARCH

QUICKLINKS AND VIEW OPITONS

  • Categories of Articles
  • Summary View
  • Headline View
  • Archive of Quotes
  • Contact Us
  • Follow @fatnews

    Those who don’t lose at least 3% in 3 months with Qsymia (phentermine plus topiramate)


    Posted by .(JavaScript must be enabled to view this email address)
    Wednesday, July 18, 2012 3:30 pm Email this article

    Subjects who don't lose at least 3% of their body weight after 3 months on the lower dose of Qsymia (7.5 mg phentermine plus 46 mg topiramate extended-release) are "unlikely to achieve and sustain weight loss with continued treatment at this dose," notes the press release from the U.S. FDA.

    At this point, it should be evaluated based on weight loss if the drug should be discontinued or if the dose should be increased to the higher dose.

    Those who don’t lose at 3% in 3 months unlikely to lose more

    Evaluate weight loss after 3 months to decide if you should increase the dose or discontinue the drug

    “Patients who did not lose at least three percent of their body weight by week 12 of treatment with Qsymia were unlikely to achieve and sustain weight loss with continued treatment at this dose.

    “Therefore, response to therapy with the recommended daily dose of Qsymia should be evaluated by 12 weeks to determine, based on the amount of weight loss, whether to discontinue Qsymia or increase to the higher dose. 

    “If after 12 weeks on the higher dose of Qsymia, a patient does not lose at least five percent of body weight, then Qsymia should be discontinued, as these patients are unlikely to achieve clinically meaningful weight loss with continued treatment.”

    Reference

    FDA. FDA approves weight-management drug Qsymia. July 17, 2012.
    http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312468.htm

    More Info

    More info about Qsymia here

    Drug companies website:

    Other Articles

    Other articles about Qsymia (formerly Qnexa)

    Articles on the same subject can be found here:


    COMMENTS

    Please feel free to share your comments about this article.


    Name:

    Email:

    Comments:

    Please enter the word you see in the image below:


    Remember my personal information

    Notify me of follow-up comments?



    © Copyright 2003-2021 - Larry Hobbs - All Rights Reserved.